1. ¹INSERM U749, Faculté de Pharmacie, Châtenay-Malabry, Hauts-de-Seine, France
2. ²UMR 891 INSERM, Institut Paoli-Calmettes, Marseille, Bouches-du-Rhône, France
3. ³INSERM U866, Dijon, Côte d'Or, France
4. ⁴University of Bourgogne, Dijon, Côte d'Or, France

Correspondence: Dr J Breard, INSERM U749, Faculte de Pharmacie, 5 rue JB Clement, Châtenay-Malabry, Hauts de Seine 92290, France. E-mail: jacqueline.breard@u-psud.fr

Received 22 February 2008; Revised 15 May 2008; Accepted 21 May 2008; Published online 16 June 2008.

Abstract

A pair of isogenic colon carcinoma cells, SW480 and 620, was used to investigate the mechanisms of acquired tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistance during tumour progression. Whereas primary tumour SW480 cells are sensitive to TRAIL-induced apoptosis, metastatic SW620 cells are resistant. The apoptotic signalling activated by TRAIL in SW480 cells is a type II pathway. We show that in SW620 cells, although caspase-8 is recruited and activated at the death-inducing-signalling complex and Bid is cleaved, this does not lead to caspase-9 activation. Comparison of Bcl-2, Bcl-xL and Mcl-1 levels in both cell lines showed no difference. In SW620 cells transfected with a tBid-GFP construct, tBid-GFP was correctly localized to the mitochondria. Thus, the resistance of SW620 cells is at the level of the mitochondria that can withstand large amounts of tBid. Although caspase-3 was directly cleaved by caspase-8 in SW620 cells to yield the p20 fragment, no further autocatalytic maturation into the p17 fragment was observed. We show that, in contrast to SW480 cells, the SW620 cell line expresses high amounts of X-linked inhibitor of apoptosis (XIAP). Downregulation of XIAP with bortezomib or small-interfering RNA was sufficient to restore the sensitivity of SW620 cells to TRAIL-induced apoptosis in the absence of SMAC/Diablo or cytochrome c release from the mitochondria. Thus, SW620 cells have developed a dual resistance to TRAIL-induced apoptosis: a block at the level of the mitochondria and, after a conversion to a type I pathway, an increased expression of XIAP which inhibits this pathway.